SciELO - Scientific Electronic Library Online

vol.79 issue4Relationship of Ventricular Function and Morphometry in Patients with Symptomatic Aortic StenosisSurvey on Cardiovascular Risk Factors in Bariloche author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista argentina de cardiología

On-line version ISSN 1850-3748


ARIAS, Aníbal M. et al. Cost-Effectiveness Analysis of Alternative Strategies for the Management of Patients with Cryptogenic Stroke and Patent Foramen OvaleCost-Effectiveness Analysis of Alternative Strategies for the Management of Patients with Cryptogenic Stroke and Patent Foramen Ovale. Rev. argent. cardiol. [online]. 2011, vol.79, n.4, pp.337-343. ISSN 1850-3748.

Background Patent foramen ovale (PFO) has been associated with cryp-togenic stroke (CS). There are still some controversies about the best treatment to prevent recurrences in patients with CS and PFO. Our region lacks cost-utility analysis of the management of these patients. Objectives To construct a decision model for the management of patients with CS and PFO and to establish the cost-utility ratio of three alternative strategies. Material and Methods We conducted a cost-utility analysis based on a decision tree with a time horizon of 4 years considering three strategies: aspirin (ASA), anticoagulants (AC) or percutaneous device closure of the PFO. The benefits were expressed in QALYs. A payment threshold of ARS $28,000 was established and a sensitivity analysis was performed. Results Anticoagulants were more expensive compared to ASA (additional cost of ARS $1,315) and produced less benefits (incremental (QALY -0.063). Percutaneous device closure had an additional cost of ARS $89,876 per QALY gained compared to ASA. This cost exceeds the predetermined payment threshold. After performing the sensitivity analysis, ASA remained as the strategy with the best cost-utility ratio; however, when the probability of recurrences with this drug increases to 35%, anticoagulants present an incremental cost-utility ratio of ARS $1.356/QALY. Conclusion According to this model, in patients with CS and PFO, ASA would be the strategy with the best cost-utility ratio in our environment unless recurrences develop; in this case the use of anticoagulants would be more appropriate.

Keywords : Patent foramen oval; Cryptogenic stroke; Therapeutics; Economic evaluation; Cost-utility; Model.

        · abstract in Spanish     · text in Spanish     · English ( pdf ) | Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License